Efflux Pump Blockers in Gram-Negative Bacteria: The New Generation of Hydantoin Based-Modulators to Improve Antibiotic Activity

Ewa Otrebska-Machaj (1, 2) , Jacqueline Chevalier (1) , Jadwiga Handzlik (2) , Ewa Szymánska (2) , Jakub Schabikowski (2) , Jean-Michel Bolla (1) , Gérard G Boyer (1) , Katarzyna Kiéc-Kononowicz (2) , Jean-Marie J Pagès (1) , Sandrine Alibert (1)

1 TMCD2 - Transporteurs membranaires, chimioresistance et drug-design
2 Department of Technology and Biotechnology of Drugs

Multidrug resistant (MDR) bacteria are an increasing health problem with the shortage of new active antibiotic agents. Among effective mechanisms that contribute to the spread of MDR Gram-negative bacteria are drug efflux pumps that expel clinically important antibiotic classes out of the cell. Drug pumps are attractive targets to restore the susceptibility toward the expelled antibiotics by impairing their efflux activity. Arylhydantoin derivatives were investigated for their potentiation of activities of selected antibiotics described as efflux substrates in Enterobacter aerogenes expressing or not AcrAB pump. Several compounds increased the bacterial susceptibility toward nalidixic acid, chloramphenicol and sparfloxacin and were further pharmacomodulated to obtain a better activity against the AcrAB producing bacteria.

Keywords: antibiotics; AcrAB pump; efflux pump blocker; hydantoin; multidrug resistance

Domains: Chemical Sciences; Medicinal Chemistry; Life Sciences [q-bio]; Microbiology and Parasitology; Bacteriology

Ewa Otrebska-Machaj, Jacqueline Chevalier, Jadwiga Handzlik, Ewa Szymánska, Jakub Schabikowski, et al.. Efflux Pump Blockers in Gram-Negative Bacteria: The New Generation of Hydantoin Based-Modulators to Improve Antibiotic Activity. Frontiers in Microbiology, 2016, 7, pp.622. ⟨10.3389/fmicb.2016.00622⟩. ⟨hal-01463003⟩